Fulcrum Therapeutics, Inc. (FULC) Stock
FULC Key Statistics
About Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical firm committed to developing life-improving treatments for patients in the United States afflicted by genetically defined diseases with significant unmet medical needs. Its leading investigational therapies include losmapimod, a small molecule targeting facioscapulohumeral muscular dystrophy, and FTX-6058, an orally administered fetal hemoglobin inducer for sickle cell disease and related hemoglobinopathies, such as beta-thalassemia. Beyond these, Fulcrum is actively engaged in discovering new drug targets for various rare conditions, encompassing neuromuscular, muscular, central nervous system, and hematologic disorders, alongside cardiomyopathies and pulmonary diseases. The company has established key collaborations, notably a research and discovery partnership with Acceleron Pharma Inc. to identify biological targets within the pulmonary disease area, and a strategic licensing and development agreement with MyoKardia, Inc. focused on novel targeted therapies for genetic cardiomyopathies. Incorporated in 2015, Fulcrum Therapeutics, Inc. maintains its headquarters in Cambridge, Massachusetts.
CEO: Alexander C. Sapir. Company website
FULC — Frequently Asked Questions
What is the FULC stock price today?
Fulcrum Therapeutics, Inc. (FULC) trades at $3.74, up 0.54% on the day, as of Nov 12, 2026 09:38 UTC.
What is Fulcrum Therapeutics, Inc.'s market cap?
Fulcrum Therapeutics, Inc. has a market capitalisation of $285.35M, calculated from the live FULC share price and shares outstanding.
What is the P/E ratio of FULC?
FULC has no meaningful price-to-earnings ratio: Fulcrum Therapeutics, Inc. lost $1.21 per share over the last twelve months, and a P/E is only defined on positive earnings.
How much revenue does Fulcrum Therapeutics, Inc. make?
Fulcrum Therapeutics, Inc. generated revenue of $0.00 over the trailing twelve months.
What is the 52-week range for FULC?
FULC has traded between $2.83 and $15.74 over the past 52 weeks, and the last price is 76.2% below that high.
Is Fulcrum Therapeutics, Inc. profitable?
Yes. Fulcrum Therapeutics, Inc. keeps 0.00% of revenue as net income over the trailing twelve months.
What is the analyst price target for FULC?
Wall Street analysts rate FULC Buy, with an average price target of $3.60, 3.7% below the current price.
What sector is Fulcrum Therapeutics, Inc. in?
Fulcrum Therapeutics, Inc. is classified under the Healthcare sector and the Biotechnology industry, and is domiciled in US.
Who is the CEO of Fulcrum Therapeutics, Inc.?
Alexander C. Sapir is the chief executive of Fulcrum Therapeutics, Inc., which employs 9 people.
Where can I track FULC in real time?
QFI Terminal shows FULC with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See FULC live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open FULC in Terminal See plans